Development and structure-activity relationship study of SHP2 inhibitor containing 3,4,6-trihydroxy-5-oxo-5H-benzo[7]annulene
作者:Bohee Kim、Seungjin Jo、Sung Bum Park、Chong Hak Chae、Kwangho Lee、Byumseok Koh、Inji Shin
DOI:10.1016/j.bmcl.2019.126756
日期:2020.1
a small molecule targeting SHP2 have published, however, there are limitations on discovery of SHP2 phosphatase inhibitors due to the polar catalytic site environment. Allosteric inhibitor can be an alternative to catalytic site inhibitors. 3,4,6-trihydroxy-5-oxo-5H-benzo[7]annulene 1 was obtained as an initial hit with a 0.097 μM of IC50 from high-throughput screening (HTS) study. After the structure-activity
SHP2是一种由PTPN11基因编码的非受体蛋白酪氨酸磷酸酶,在细胞生长和增殖中起着重要作用。已经报道了SHP2的激活突变是多种人类疾病的原因,例如实体瘤,白血病和Noonan综合征。SHP2抑制剂的发现可能是治疗癌症和SHP2相关人类疾病的有效候选者。关于靶向SHP2的小分子的一些报道已经发表,但是,由于极性催化位点环境,在SHP2磷酸酶抑制剂的发现上存在局限性。变构抑制剂可以替代催化部位抑制剂。以0.097μM的IC 50初步获得3,4,6-三羟基-5-氧代-5H-苯并[7]环戊烯1来自高通量筛选(HTS)研究。在进行结构活性关系(SAR)研究后,化合物1仍然显示出对SHP2最有效的活性。此外,1和2j对表达2D和3D MDA-MB468的SHP2发挥了良好的效力。